Singapore's COVID‐19 Genomic Surveillance Programme: Strategies and Insights From a Pandemic Year
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.70060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Hao Yi Tan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Communicable Diseases Group, Ministry of Health, Singapore. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Whole Genome Sequencing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
During the COVID‐19 pandemic, genomic surveillance was crucial for monitoring virus spread and identifying variants. Effective surveillance helped understand transmission dynamics. Singapore had success in combating COVID‐19 through its surveillance programmes. This paper outlines Singapore's strategy and its impact on public health during the transition to endemicity over 54 weeks from February 2022 to February 2023.
Methods
In May 2022, Singapore expanded its acute respiratory infections (ARI) surveillance to enhance COVID‐19 detection. COVID‐19–positive samples from ARI cases were sent to the National Public Health Laboratory for whole genome sequencing (WGS). WGS data informed public health actions based on transmission origins and case severity.
Results
Over 54 weeks, NPHL sequenced 18,918 (73%) samples. Analysis showed 29% imported and 71% local cases. Severe cases accounted for 12% and were mostly elderly, specifically those aged 80 years old and above. Variant analysis identified 11 predominant variants and 288 subvariants. Omicron BA.2, BA.5 and XBB were initially dominant, followed by increased variant heterogeneity. Severe cases mirrored these trends.
Conclusion
Genomic surveillance was integral in Singapore's COVID‐19 response, guiding timely public health decisions. Effective variant tracking supported proactive measures. The experience underscores the importance of genomic surveillance for future pandemic preparedness and emerging disease detection, emphasising its role in shaping pandemic responses and global health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Communicable Diseases Group, Ministry of Health, Singapore.
- Health Systems Group, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- National Public Health Laboratory, Ministry of Health, Singapore.
- Asia Centre for Health Security, Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
ORCID-Profile: Hao Yi Tan
Zitieren
APA
Tan, H. Y., Khamis, N. H., Goh, A., Mah, T. K. L., Yeo, B., Ngan, J. Y., Ding, Y., Lin, C., Chae, S. R., Lee, P., & Ho, Z. J. M. (2024). Singapore's COVID‐19 Genomic Surveillance Programme: Strategies and Insights From a Pandemic Year. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70060
Vancouver
Tan HY, Khamis NH, Goh A, Mah TKL, Yeo B, Ngan JY, et al. Singapore's COVID‐19 Genomic Surveillance Programme: Strategies and Insights From a Pandemic Year. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.70060
BibTeX
@article{Tan2024,
author = {Tan, Hao Yi and Khamis, Nur Huda and Goh, Alvin and Mah, Tania K L and Yeo, Benny and Ngan, Jie Yin and Ding, Yichen and Lin, Cui and Chae, Sae-Rom and Lee, Phoebe and Ho, Zheng Jie Marc},
title = {Singapore's COVID‐19 Genomic Surveillance Programme: Strategies and Insights From a Pandemic Year},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.70060}
}
EUVIMED